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this rearrangement, the myc proto-oncogene in chromosome
8 is translocated to the immunoglobulin heavy chain locus inntroduction
eoplastic diseases affect about 1:1000 women during
regnancy.1 This incidence varies according to region, age and
he presence or absence of pre-invasive diseases.2
Lymphoma is the fourth most diagnosed cancer in this
eriod, behind breast tumors, cervical cancer and melanoma.3
ts frequency has risen with the tendency in modern society
f postponing pregnancy.4
The most common lymphoma in pregnant patients is
odgkin’s lymphoma, since its incidence spike coincides
ith the female fertile age. Any link between non-Hodgkin
ymphoma and pregnancy has still not been elucidated,
ith few case reports being found in the medical literature
orldwide.3,4
Burkitt’s lymphoma is a very aggressive germinal B-cell
ymphoma, frequently presenting extranodal sites. It is the
econd most common lymphoma in children, but it is very rare
n adults. Three clinical variants are known: endemic, sporadic
nd immunodefﬁciency-related.5
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eserved.In the sporadic form, the primary location of the disease
involves the abdomen in 80% and the mandible in 14% of
patients. In the endemic form, the mandibular and maxil-
lary are involved in 60% of patients, abdominal commitment
in 58% of cases, followed by the central and paraspinal ner-
vous systems. An important geographic difference between
these two forms is the association of Epstein–Barr virus (EBV)
with the endemic form. However, only 15–20% of Burkitt’s lym-
phomas seen in Europe and in the USA are associated with
EBV. The frequency of this association in South America seems
intermediate and, in Brazil, a frequency of 70% for EBV asso-
ciated with Burkitt’s lymphoma has been reported.5
Burkitt’s lymphoma was the ﬁrst identiﬁed neoplasm
whose pathogenesis involved a chromosomal translocation as
demonstrated by molecular biology. This mutation involves a
translocation between the distal part of the long arm of chro-
mosome 8 and chromosome 14 [t(8;14) (q24;q32)]. As a result ofmpus I, Jardim Universitário S/N, Castelo Branco, 58051-900 João
chromosome 14.6
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 2 – Soft tissue mass in the upper third of the
abdomen with air-ﬂuid level, dilation of the anterior128  rev bras hematol hem
Case  report
A 25-year-old female patient born in Santa Rita, state of
Paraíba consulted with a slight stinging abdominal pain in
the left hypochondriac and lumbar regions, associated with
diarrhea and melena for three months. The result of a b-
HCG test, performed because of amenorrhea, was positive. The
obstetric ultrasonography (USG) revealed a four-week two-day
pregnancy. After one month, there was an increase in the pain,
associated with nausea and weight loss. A new obstetric USG,
performed during prenatal care, showed a morphologically
normal fetus (12 weeks), in addition to right colon thickening
in the mother, with an extensive (5.0 cm × 3.0 cm)  vascular-
ized hypoechogenic formation next to the hepatic angle. The
patient was asked to urgently seek a gastroenterologist.
With signiﬁcant worsening of the abdominal pain and
acute exacerbation of the condition, the patient went to the
Hospital Universitário Lauro Wanderley, where she was admit-
ted to perform more  tests. A computer tomography showed a
soft tissue mass in the upper third part of the abdomen, with
air-ﬂuid level, and dilation of anterior intestinal loops with
partial obstruction (Figures 1 and 2).
A further abdominal USG revealed an extensive
(10.6 cm × 5.4 cm)  echo-complex mass in the right hypochon-
drial region, with a heterogeneous aspect (solid/cystic). A
colonoscopy revealed a vegetative lesion of about 15 cm
occupying around 90% of the intestinal lumen.
The patient was submitted to enterectomy and typhlec-
tomy, in addition to right segmental colectomy with primary
latero-lateral ileocolonic anastomosis. Surgery was completed
without complications and the patient evolved well after the
procedure, without complaints of bleeding or pain in the lower
abdomen. An evaluation of the fetal was made conﬁrming
preserved vitality. The patient was prescribed natural proges-
terone (400 mg/day) in order to keep the uterus quiescent.
The mass removed during surgery was submitted to anato-
mopathological evaluation revealing medium and large cell
non-Hodgkin lymphoma. Immunohistochemistry identiﬁed
Figure 1 – Heterogeneous mass occupying almost all of the
ascending and transverse colonic lumen with dilation and
signs of distal obstruction.intestinal loops and partial obstruction.
features of Burkitt’s lymphoma. After discharge, the patient
was referred for onco-hematological and obstetric care.
The staging of the lymphoma revealed isolated abdominal
disease, with no bone marrow or cerebrospinal ﬂuid involve-
ment; it was classiﬁed as Murphy II-B. A 21-day regimen
of rituximab IV (375 mg/m2 – Day 1), cyclophosphamide IV
(500 mg/m2 per day – Day 1–3), vincristine IV (2 mg  – Day 1
and Day 8), doxorubicin IV (60 mg/m2 – Day 1), oral prednisone
(60 mg/m2 – Day 1–5) (COPAD-R) was started following the
LMB-96 protocol. Moreover, prophylaxis of the central nervous
system was carried out using intrathecal chemotherapy: dexa-
methasone (2 mg)  and methotrexate (12 mg  – Day 2 and Day
5).7–9
The patient was advised about the aggressiveness of
the condition and the possible risks to the fetus during
chemotherapy, but chose not to interrupt pregnancy. The
patient had a good evolution with clinical improvement.
During obstetric care, another morphological obstetric USG
revealed a non-ectopic pregnancy with an echographic age
of 19.1 weeks – in addition to an abdominal USG, which
showed a solid abdominal mass (8.6 cm × 10.8 cm)  in a medial
and slightly left position, which was heterogeneous with
irregular edges. An USG performed the following week showed
a non-ectopic pregnancy with echographic age of 20.3 weeks
and preserved fetal morphology, and a solid abdominal
mass (6.6 cm × 3.6 cm × 5.0 cm), identical to the one previously
described, indicating that there was a decrease in size after the
beginning of chemotherapy.
After four cycles of chemotherapy, the patient evolved with
a new acute abdominal condition. Laparotomy showed a per-
foration in the proximal jejunum, and so another enterectomy
and urgent caesarian section (33rd week of pregnancy) were
performed. A healthy female child of 1815 g was delivered.
The segment removed in the second enterectomy was sent
for anatomopathological study, which showed no disease. A
computer tomography after birth was normal.The patient in this study died about three months after the
date of birth, the victim of sudden death with no evidence of
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iscussion
urkitt’s lymphoma, although very aggressive, is highly
reatable.10 The objective of treatment is to eliminate the
argest number of malignant cells possible and induce com-
lete remission, in other words, the disappearance of all
vidence of the disease. Patients with aggressive and fast
rowing lymphomas are frequently treated with combined
hemotherapy. Intensive chemotherapy with multiple drugs
ay be very effective against aggressive lymphomas. The
rognosis of Burkitt’s lymphoma depends on the extent of the
isease and the time interval between the ﬁrst complaints and
iagnosis. The disease-free survival rate is between 75% and
5% in adults.6
There is no unique option for chemotherapeutic treat-
ent of this kind of lymphoma. Today, the chemotherapeutic
reatment consists in short-duration intensive regimens that
nclude agents such as methotrexate, cyclophosphamide, vin-
ristine, doxorubicin and prednisone. Methotrexate is used in
ost of the big centers, but it is highly toxic and is respon-
ible for most of the risk during pregnancy. The treatment is
omplemented with prophylaxis for infections. Relapse some-
imes occurs during the ﬁrst year, and is a particularly poor
rognostic sign.11
The treatment of a pregnant woman with cancer is always
 delicate decision, since it involves risks for the mother and
hild, the wishes of the patient and the opinions of the oncol-
gist, the obstetrician and the neonatologist. The potential
ffects of antineoplastic agents to the fetus include immedi-
te effects, such as abortion and teratogenesis with speciﬁc
amage to one or more  organs, and late effects, such as delay
n growth and gonadal dysfunction.1
The choice of the COPAD-R regimen following the LMB-96
rotocol,7–9 aiming at greater practicality with fewer risks for
he patient, was very successful, ensuring remission of the
isease and completion of the pregnancy.
The rare occurrence of lymphoma during pregnancy pre-
ents large prospective studies being performed to examine
ssues about diagnosis, management and the outcomes. The
iterature about the subject is poor and based on retrospective
nalysis, and so further studies are necessary.
onclusionhe association of cancer and pregnancy is a very rare con-
ition. During a long time, the occurrence of cancer during
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pregnancy was related to the idea of a very aggressive dis-
ease, with reserved prognosis and little perspective to treat.
However, recently, there have been reports of cases in which
chemotherapy was successfully used in pregnant women.
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